Next 10 |
2024-07-03 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:00 ET It was a rough first half of the year for Cathie Wood. The co-founder, CEO, and investor at Ark Invest saw her family of aggressive growth exchange-traded funds lose badly to the market. But she's not throwing in the towel. Wood publishes Ark's daily transactions,...
2024-07-01 14:34:13 ET Summary Beam Therapeutics Inc. is a gene editing company focused on precision genetic medicines through base editing. The company has notable collaborations with Pfizer and other pharma concerns, with several pipeline milestones in 2024. The company is m...
2024-06-28 10:28:50 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various c...
2024-06-27 16:48:49 ET Summary The small biotech sector has badly underperformed the major market indices so far in 2024. However, that could change as the Federal Reserve cuts interest rates and/or M&A deal volume picks up across the industry. Today, we highlight three sm...
2024-06-26 07:37:15 ET More on Intellia Therapeutics Intellia Therapeutics Presents Promising In Vivo CRISPR Results Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies Intellia Therapeutics, Inc. (NTLA) Q1 2024 Earnings Call Transcript Intellia...
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financia...
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapy Follow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28 in the three patients who previously received the lowest dose in the Phase 1 dose...
2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...
2024-06-24 16:00:08 ET Dae Gon Ha from Stifel Nicolaus issued a price target of $80.00 for NTLA on 2024-06-24 12:15:00. The adjusted price target was set to $80.00. At the time of the announcement, NTLA was trading at $25.22. The overall price target consensus is at $126...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-07-03 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:00 ET It was a rough first half of the year for Cathie Wood. The co-founder, CEO, and investor at Ark Invest saw her family of aggressive growth exchange-traded funds lose badly to the market. But she's not throwing in the towel. Wood publishes Ark's daily transactions,...